RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Diluted EPS

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndDiluted EPS (USD)YoY (%)
Dec 31, 202438.3+10.27%
Dec 31, 202334.8-9.03%
Dec 31, 202238.2-46.89%
Dec 31, 202172+135.81%
Dec 31, 202030.5+65.33%
Dec 31, 201918.5-13.29%
Dec 31, 201821.3+105.90%
Dec 31, 201710.3+34.29%
Dec 31, 20167.7+39.49%
Dec 31, 20155.5+79.80%
Dec 31, 20143.1-19.42%
Dec 31, 20133.8-43.56%
Dec 31, 20126.8

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)